Elevance Excels in Q2: Strong Financial Performance Boosts Market Confidence
Elevance's robust Q2 results have captivated the market's attention, with their stock enjoying a 5% uptick on the back of the news. Top and bottom line estimates were not merely met, but surpassed, as the company reported a 12.7% overall growth in top-line revenue, and a striking 18.4% quarter-on-quarter growth in Carelon, yielding $43.3 billion and $11…
Keep reading with a 7-day free trial
Subscribe to The Healthcare Economy to keep reading this post and get 7 days of free access to the full post archives.